DAVID ERRITZOE

David Erritzoe
Academic clinical lecturer in psychiatry

What we (don’t) know about psychedelic microdosing

What is microdosing, why do people microdose, and what is the evidence for its effect? A new “self-blinding experiment” approach will be presented, and preliminary data from an Imperial College prospective online survey will be shown and discussed.

The “self-blinding experiment” is part of the Beckley/Imperial Research Programme.

David qualified as a medical doctor at Copenhagen University Medical School in 2001 and currently holds an Academic Clinical Lectureship in Psychiatry at Imperial College London. Alongside his clinical training in medicine/psychiatry, David has been involved in psychopharmacological research, using brain-imaging techniques such as PET and MRI. Initially working at Columbia University in New York, he then undertook a PhD at University Hospital Rigshospitalet in Copenhagen. Since 2009, under the mentorships of Profs Anne Lingford-Hughes and David Nutt at Imperial College London, he has conducted post-doc imaging research in the neurobiology of addictions and major depression. Together with Prof Nutt and Dr Carhart-Harris he is also investigating the neurobiology and therapeutic potential of MDMA and classic psychedelics.